surmount-1 trial tirzepatide non-diabetic weight loss vs semaglutide: A new battle in obesity treatment SURMOUNT-1 Trial - Cardionerds Twitter

Tirzepatide has been shown to lower body weight and fat mass by decreasing food intake through appetite regulation and modulation of fat utilisation, with an associated improvement in health-related quality of life [17,18,19]

In SURMOUNT-1 the 15 mg arm averaged 22.5% body weight loss at 72 weeks, only modestly higher than the 10 mg arm at 21.4%

Ranging in length from 7.1 cm to 16.5 cm and in diameter from 1.1 cm to 3.8 cm, they comply with the recommended progressive increases

That way, weight loss lasts

Any form of weight loss can lead to muscle loss , and losing weight with Mounjaro is no different

The direct relationship between change in eGFR and change in BP was also observed at 12 weeks (Extended Data Table 3)